Global OTC leader grows in China
This article was originally published in The Tan Sheet
Executive Summary
Japanese firm Taisho Pharmaceutical, an OTC manufacturer and a majority stakeholder of Chinese firm Shanghai Dazhengli Health Care, purchased the 15 percent of the firm held by the Guan Shen Yuan Group for 14.7994 million yuan ($2.2 million at Sept. 24 conversion rates). Taisho set up Shanghai Dazhengli Health Care in 1997 to sell its Libogen products in China. Shanghai Dazhengli can produce more than 20 million bottles of Lipovitan D nutrient drink annually. Taisho wants to expand its production and sales in China from Shanghai